Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.555 AUD | -2.63% | -13.28% | -16.54% |
12/06 | Inoviq's Neuro-Net Technology Opens Opportunities for Alzheimer’s Diagnostics, Treatment; Shares Surge 20% | MT |
07/06 | Inoviq Requests Trading Halt | MT |
Business Summary
Number of employees: 15
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Telomerase Reverse Transcriptase
91.2
%
| 0 | 99.0 % | 0 | 91.2 % | +32.61% |
Molecular Nets
8.8
%
| 0 | 1.0 % | 0 | 8.8 % | +1,128.37% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
60.4
%
| 0 | 1.0 % | 0 | 60.4 % | +8,350.67% |
United States
39.6
%
| 0 | 99.0 % | 0 | 39.6 % | -42.49% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 07/16/07 |
Mark Edwards
DFI | Director of Finance/CFO | - | 02/22/02 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 20/21/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Williams
CHM | Chairman | 70 | 29/11 |
Philip Powell
BRD | Director/Board Member | 65 | 18/19/18 |
Geoff Cumming
BRD | Director/Board Member | - | 28/20/28 |
Robert Johnston
BRD | Director/Board Member | - | 18/19/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 92,018,702 | 79,458,065 ( 86.35 %) | 0 | 86.35 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.54% | 3.48Cr | |
+31.38% | 5.27TCr | |
+37.49% | 3.9TCr | |
-9.28% | 3.85TCr | |
+28.25% | 3.04TCr | |
-12.26% | 2.64TCr | |
+11.23% | 2.61TCr | |
+44.54% | 1.42TCr | |
+32.23% | 1.26TCr | |
-5.37% | 1.15TCr |
- Stock Market
- Equities
- IIQ Stock
- Company INOVIQ Ltd